| 生物活性 |
GPX4-AUTAC is an autophagy-mediated degrader (AUTAC) targeting GPX4, composed of the inhibitor ML162-yne (MS-X46505), the degradation tag FBnG (MS-O28293), and a glycol linker (MS-F89749); it promotes ubiquitination of GPX4 by the E3 ligase TRAF6 and enhances its binding to GPX4 and p62, thereby achieving selective autophagy-dependent degradation of GPX4, significantly inducing ferroptosis, and exhibiting potent anticancer activity in breast cancer cells, breast cancer-derived organoids (PDOs), and MDA-MB-231 tumor xenograft mouse models, with strong synergistic effects when combined with Sulfasalazine (SAS) (MS-R53590) or chemotherapeutic agents (Paclitaxel or Cisplatin (MS-E94993)). |
体外研究 (In Vitro) |
GPX4-AUTAC (5-80 μM,12-72 小时) 以剂量和时间依赖性方式显著降低 MDA-MB-231 和 MCF-7 细胞中 GPX4 的蛋白水平,但对 GPX4 的 mRNA 水平几乎没有影响。
GPX4-AUTAC (20-40 μM,24 小时) 可有效降低卵巢癌、肺癌、黑色素瘤和胶质瘤细胞中 GPX4 的蛋白水平。
GPX4-AUTAC (10 μM,24-96 小时,37-57℃) 持续下调 GPX4 蛋白水平长达 96 小时,并显著增强 MDA-MB-231 和 MCF-7 细胞中热变性的完整细胞和细胞裂解物中 GPX4 的热稳定性。
GPX4-AUTAC (5-80 μM,24 小时) 选择性降解 GPX4,但不影响其他硒蛋白的表达,例如 GPX1、TXNRD1 (GPX4 同源物) 或 HK2 (TRAF6/p62 底物)。
GPX4-AUTAC 选择性降解 GPX4 并诱导肿瘤细胞 (MDA-MB-231 细胞) 的铁死亡,而对正常细胞 (MCF-10A 细胞) 的影响极小。
GPX4-AUTAC (10 μM,24 小时) 以自噬依赖的方式加速 HEK293T 细胞中 GPX4 降解,增加 GPX4 的多泛素化,特别是内源性和外源性 K63 连接泛素链。。
GPX4-AUTAC (10-40 μM,12 小时) 可被 PYR-41、NH4Cl 和 3-MA 逆转,从而减少 MDA-MB-231 细胞中 GPX4 的下调。
GPX4-AUTAC (24 小时) 可诱导 GPX4 和 p62 共定位,并增加 PDOs 中 GPX4 与 LC3B 或 LAMP2 的共定位。
GPX4-AUTAC (40 μM,24 小时) 选择性靶向 GPX4,且铁死亡在 MDA-MB-231 细胞中显著富集。
GPX4-AUTAC (5-40 μM,72 小时) 具有特异性的铁死亡诱导作用,显著增强 MDA-MB-231 细胞中脂质 ROS 并促进 Fe2+ 的积累,但仅在 MCF-7 细胞中被铁死亡抑制 Ferrostatin-1 (Fer-1) (MS-K98895) 完全挽救。
GPX4-AUTAC (5-80 μM) 可诱导 MDA-MB-231 细胞的铁死亡并伴随线粒体功能障碍 (形态异常、内容致密和嵴破坏) 以及 PTGS2 mRNA 水平显著升高。
GPX4-AUTAC (5-40 μM,24-96 小时) 以剂量和时间依赖性的方式抑制 MDA-MB-231 和 MCF-7 细胞细胞活力和增殖,且对 GPX4 的敲低不敏感。
GPX4-AUTAC (5-40 μM,4 天) 显著抑制 PDOs 生长,减少其直径和明视野,而 GPX4 高表达的 PDOs 增加对 GPX4-AUTAC 的敏感性。
GPX4-AUTAC (10-20 μM,4 天) 可下调 GPX4 表达,并诱导高水平 4-HNE 的铁死亡,抑制低水平 Ki67 的 PDOs 中癌细胞增殖。
GPX4-AUTAC 与 Sulfasalazine 联合使用相比于单独使用 Sulfasalazine 而言,可在 MDA-MB-231 和 MCF-7 细胞以及 PDOs 中诱导更显著的铁死亡并具有更强的抗癌作用。
GPX4-AUTAC (10 μM,72 小时或 4 天) 可使 MDA-MB-231 和 HCC1806 细胞对化疗敏感,并与化疗药物 (Paclitaxel or Cisplatin) 联合使用可协同抑制细胞活力和增殖以及 PDOs 的生长。
Cell Viability Assay
| Cell Line: |
MCF-7 cells |
| Concentration: |
5, 10, 20, 40 μM |
| Incubation Time: |
72 h after Fer-1, Z-VAD-FMK, Nec-1, Olaparib or VX765 1 h |
| Result: |
Had a specific ferroptosis inductive effect, only fully rescued by the ferroptosis inhibitor ferrostatin-1 (Fer-1), but not by the inhibitor of apoptosis (Z-VAD-FMK), necroptosis (Nec-1), parthanatos (Olaparib), or pyroptosis (VX765) in MCF-7 cells.
|
Cell Viability Assay
| Cell Line: |
MDA-MB-231 cells, MCF-7 cells |
| Concentration: |
MDA-MB-231 cells, MCF-7 cells (5, 10, 20, 40 μM), shNT, shGPX4 cells (10, 20, 40, 80 μM) |
| Incubation Time: |
72 h |
| Result: |
Dose-dependently inhibited tumor cell viability in both MDA-MB-231, MCF-7 and shGPX4 cells.
|
Cell Proliferation Assay
| Cell Line: |
MDA-MB-231 cells, MCF-7 cells |
| Concentration: |
5, 10 μM |
| Incubation Time: |
24, 48, 72, 96 h |
| Result: |
Dose- and time-dependently inhibited tumor cell proliferation in both MDA-MB-231 and MCF-7 cells.
|
Western Blot Analysis
| Cell Line: |
MDA-MB-231 cells, MCF-7 cells, MCF-10A cells |
| Concentration: |
MDA-MB-231 cells, MCF-7 cells, MCF-10A cells (5, 10, 20, 40, 80 μM) |
| Incubation Time: |
12, 24, 48, 72 h |
| Result: |
Significantly reduced the expression of GPX4 protein in a dose- and time-dependent manner.
Significantly reduced the expression of GPX4 in MDA-MB-231 cells with minimal effect on MCF-10A cells at 24 h.
|
Western Blot Analysis
| Cell Line: |
MDA-MB-231 cells, MCF-7 cells |
| Concentration: |
10 μM |
| Incubation Time: |
24, 48, 72, 96 h |
| Result: |
Continuously down-regulated GPX4 protein level for 96 h after wash-out in MDA-MB-231 and MCF-7 cells.
Significantly enhanced the thermal stability of GPX4 in heat-denatured intact cells and cell lysates in MDA-MB-231 and MCF-7 cells at 37-57℃ and 24 h.
|
Western Blot Analysis
| Cell Line: |
MDA-MB-231 cells, HEK293T cells |
| Concentration: |
10, 40 μM |
| Incubation Time: |
12 h |
| Result: |
Significantly accelerated the turnover rate of GPX4 in MDA-MB-231 cells when added CHX at 10 μM.
Down-regulated GPX4 expression, but this effect reversed by PYR-41 (an inhibitor of cell-permeable ubiquitin E1 enzyme) in MDA-MB-231 cells at 10 μM.
Enhanced the down-regulation of GPX4 promoted by overexpression of p62, but rescued by knockdown of p62 in HEK293T cells at 40 μM.
|
Real Time qPCR
| Cell Line: |
MDA-MB-231 cells, MCF-7 cells |
| Concentration: |
5, 10, 20, 40, 80 μM |
| Incubation Time: |
24 h |
| Result: |
Played a regulatory role at the post-translational level,and barely affected the mRNA level of GPX4 in both MDA-MB-231 and MCF-7 cells.
|
Immunofluorescence
| Cell Line: |
MDA-MB-231 cells |
| Concentration: |
5, 10, 20, 40 μM |
| Incubation Time: |
72 h |
| Result: |
Significantly enhanced the lipid ROS and promoted accumulation of Fe<>sup2+ in MDA-MB-231 cells.
|
|
体内研究 (In Vivo) |
GPX4-AUTAC (10-20 mg/kg,腹腔注射,每日一次,连续 10-12 天) 具有强效的抗癌活性,通过在 MDA-MB-231 肿瘤异种移植小鼠模型中优先积累并选择性降解肿瘤组织中的 GPX4 (对正常组织的影响较小),显著减少肿瘤重量和体积、GPX4 蛋白水平和 Ki67 百分比,同时升高 4-HNE 水平,且对重要器官无明显毒性。
GPX4-AUTAC (10-20 mg/kg 联用 Sulfasalazine 100 mg/kg,腹腔注射,每日一次,持续 10-12 天) 与 Sulfasalazine 协同作用,在 MDA-MB-231 肿瘤异种移植小鼠模型中通过诱导铁死亡发挥强大的肿瘤抑制活性,并且未发现可测量的毒性。
| Animal Model: |
Female BALB/c nude mice (4-6 weeks old) were injected subcutaneously into the right flank with MDA-MB-231 cells (5 × 106 cells/mouse). |
| Dosage: |
10, 20mg/kg |
| Administration: |
i.p., daily for 10-12 days when the tumor size reached 50-100 mm |
| Result: |
Selectively degraded GPX4 in tumors tissues, but not in the normal tissues including the heart, lung, liver, spleen, and kidney.
Significantly decreased tumor weights and volumes in MDA-MB-231 tumor xenograft mice model.
Markedly decreased the protein level of GPX4 in MDA-MB-231 tumor xenograft mice model.
Effectively decreased percentage of Ki67, but increased percentage of Ki67 4-HNE in MDA-MB-231 tumor xenograft mice model. |
| Animal Model: |
Female BALB/c nude mice (4-6 weeks old) were injected subcutaneously into the right flank with MDA-MB-231 cells (5 × 106 cells/mouse). |
| Dosage: |
10, 20mg/kg or Sulfasalazine 100 mg/kg |
| Administration: |
i.p., daily for 10-12 days when the tumor size reached 50-100 mm |
| Result: |
Had a synergistic inhibitory effect on tumor growth combined with SAS in MDA-MB-231 tumor xenograft mice model.
Significantly decreased expressions of GPX4 and Ki67 and increased expression of 4-HNE combined with SAS in MDA-MB-231 tumor xenograft mice model.
|
|